PAIN
Volume 139, Issue 2 , Pages 477-479 , 15 October 2008

Response to: Long-term trials of pregabalin and duloxetine for fibromyalgia symptoms: How study designs can affect placebo factors

Received 18 June 2008 ,Accepted 28 July 2008.

References 

  1. Staud R, Price DD. Long-term trials of pregabalin and duloxetine for fibromyalgia symptoms: how study designs can affect placebo factors. Pain. 2008;136:232–234
  2. McQuay HJ, Derry S, Moore RA, Poulain P, Legout V. Enriched enrolment with randomised withdrawal (EERW): time for a new look at clinical trial design in chronic pain. Pain. 2008;135:217–220
  3. Crofford LJ, Mease PJ, Simpson SL, Young JP, Martin SA, Haig GM, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain. 2008;136:419–431
  4. Russell IJ, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM, Detke MJ, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain. 2008;136:432–444
  5. Straube S, Derry S, McQuay HJ, Moore RA. Enriched enrolment: definition, and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. Br J Clin Pharm. 2008;16(May [Epub ahead of print]):
  6. Kaptchuk TJ, Stason WB, Davis RB, Legedza AR, Schnyer RN, Kerr CE, et al. Sham device v inert pill: randomised controlled trial of two placebo treatments. BMJ. 2006;332:391–397
  7. Rief W, Avorn J, Barsky AJ. Medication-attributed adverse effects in placebo groups: implications for assessment of adverse effects. Arch Intern Med. 2006;166:155–160
  8. Meyer FP, Tröger U, Röhl FW. Adverse nondrug reactions: an update. Clin Pharm Ther. 1996;60:347–352
  9. Demyttenaere K, Albert A, Mesters P, Dewé W, De Bruyckere K, Sangeleer M. What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors?. J Clin Psychiatry. 2005;66:859–863
  10. Meyer FP, Tröger U, Röhl FW. Reliability of symptom reports by healthy volunteers treated with placebo over several time periods. Arzneimittelforschung. 2000;50:768–771

PII: S0304-3959(08)00423-5

doi: 10.1016/j.pain.2008.07.026

PAIN
Volume 139, Issue 2 , Pages 477-479 , 15 October 2008

Article Tools